OST31-164 for Bone Cancer (OST-164-01 Trial)

"Yes, this information can be found on clinicaltrials.gov. This particular trial was originally posted on October 21st 2021 and has since been updated on October 31st 2022."

"According to the inclusion criteria laid out by the study, patients between 12 and 39 years old are eligible. There are 114 other trials for patients younger than 12 and 85 trials for patients older than 65."

"There are 23 sites for this trial, with the primary locations being Ann & Robert H. Lurie Children's Hospital of Chicago in Chicago, Illinois; Connecticut Children's in Hartford, Connecticut; and Children's Hospital of Philadelphia in Philadelphia, Pennsylvania."

"There is limited data surrounding the safety of OST31-164, as this is only a Phase 2 trial. This suggests that while there have been no studies conducted observing its efficacy, there have been some studies completed which support its safety."

"This clinical trial is recruiting 45 people with osteosarcoma between the ages of 12 and 39. Most notable, applicants are required to meet the following criteria: Note: Patients enrolled on AOST2031 are eligible for enrollment in the present study., Age and Weight, Between 12 years of age and 39 years of age at the time the Informed Consent/ Assent form is signed., Weight at least 40 kg. Diagnosis, Has histologic confirmation of osteosarcoma at diagnosis., Surgical resection of all possible sites of suspected pulmonary metastases to achieve a complete remission within 8 weeks prior to study enrollment"

"45 individuals that meet the specific requirements set forth by the study's designers need to enroll. This research is being conducted across multiple sites, like Ann & Robert H. Lurie Children's Hospital of Chicago in Chicago, Illinois and Connecticut Children's in Hartford, Connecticut."